SIMC1

Across TCGA pan-cancer cohorts, SIMC1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SIMC1 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SIMC1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SIMC1 expression acts as an unfavorable survival marker.

PDAC, UCEC, and LUAD are the cancer types where SIMC1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.361	0.826	.006	12	view →
UCEC	DFS	Median	All	0.788	1.000	.044	4	view →
LUAD	OS	Median	All	0.726	1.000	.022	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SIMC1–PDAC (DFS)

Open the PDAC breakdown →